APPLICATION
ANDA079124
TYPE
ANDA
ORIGINAL APPROVAL
2015-09-17
LATEST ACTION
2024-09-19
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
LAMIVUDINE AND ZIDOVUDINEPrescription
LAMIVUDINE 150MG, ZIDOVUDINE 300MG · TABLET · ORAL
Approval history
2024-09-19Labeling · Supplement 14 · standardAP
2024-09-19Labeling · Supplement 10 · standardAP
2023-04-19Labeling · Supplement 20 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.